Finding the Optimal Resistance Training Intensity For Your Bones

November 1, 2022 updated by: University of Waterloo

Finding the Optimal Resistance Training Intensity For Your Bones: A Randomized Controlled Trial (FORTIFY Bones)

Osteoporosis is a bone disease that can result in fractures, disability and an increased risk of premature death. Exercise is recommended for fall and fracture prevention, but health care professionals often recommend walking or lower intensity community exercise classes, which may not be effective for building bone. Further, individuals with osteoporosis are often told to avoid lifting or moving in certain ways, which creates fear and activity avoidance. Conversely, research suggests that to stimulate bone, you need higher loads on bone, with either higher intensity resistance training or impact exercise - the types of things people with low bone mass are told to avoid. Our study will examine different types of exercise intensity and how they translate to building bone in people with low bone mineral density (BMD).

Study Overview

Detailed Description

The FORTIFY Bones study will compare the effect of supervised twice-weekly progressive resistance training (PRT) at moderate or high intensity for one year to a home posture and balance exercise program on lumbar spine bone mineral density (BMD), in individuals with low bone mass not taking osteoporosis medication. As secondary analyses, we will examine the differences between each resistance training intensity and home exercise, and between resistance training intensities on all outcomes. Participants will be randomized to one of three exercise programs to be completed twice weekly: posture and balance exercise program at home, in-person, supervised progressive resistance training at 70% of estimated 1 Repetition Maximum (1RM) intensity, or in-person, supervised progressive resistance training at an 85% estimated 1RM intensity. The study is a multi-centre trial that will take place at the University of Waterloo, Toronto General Hospital, and the University of Saskatchewan. The long-term goal of this study is to generate evidence to support decision-making on the type of exercises for people with osteoporosis.

Study Type

Interventional

Enrollment (Anticipated)

324

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Ontario
      • Waterloo, Ontario, Canada
        • Recruiting
        • University of Waterloo
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

50 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age 50 or over
  • Has received 2 vaccines for COVID-19
  • Has femoral neck, total hip, or lumbar spine BMD T-score of ≤ -1, OR has been or have a FRAX probability of fracture of greater than or equal to 20% for major osteoporotic fracture or 3% or greater for hip fracture.*

    • Individuals at high risk of fracture (i.e., risk in next 10 years is >20% according to FRAX) should be offered medication for osteoporosis. We will only include individuals at high risk of fracture who have declined medication or who had been on osteoporosis medication and decided to cease taking it in the appropriate timeline (as outlined by PI's and Physician).
  • Willing to participate in 2x weekly exercise sessions
  • Self-reported as postmenopausal for ≥ 2 years, OR postmenopausal stats confirmed via blood test (female participants only)

Exclusion Criteria:

  • Is unable to communicate in English
  • Has conditions affecting bone health
  • Takes or has taken medications affecting bone in the last 12 months or longer (as determined by the research team)
  • Has had a clinical or symptomatic spine fracture in the last 12 months, or a lower/upper limb fracture in the last 6 months
  • Has had a joint replacement in the last 6 months
  • Is receiving palliative care
  • Has major surgery planned in the next 12 months
  • Has had cancer within the last 2 years (excluding non-melanoma skin cancer)
  • Has planned travel time of greater than 6 weeks
  • Has been diagnosed with dementia
  • Is already participating in moderate- or high-intensity progressive resistance training ≥ twice weekly
  • Weighs over 450 lbs
  • Has contraindications to resistance training

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Home exercise
Home exercise program, with biweekly group virtual education and exercise classes.
Participants in this arm will complete twice-weekly upper and lower body exercises at home, focused on posture and balance. Participants will meet 1:1 with an exercise physiologist who will select and prescribe exercises. Participants will also be invited to attend twice monthly virtual exercise and education sessions.
Experimental: Supervised strength training (group 1)
In-person, supervised muscle strengthening exercises twice weekly at a specific intensity.
Participants in this arm will complete twice weekly resistance training. They will focus on form initially, and then be progressed to 3 sets of 10-12 repetitions at an intensity of ~70% of estimated 1 repetition maximum.
Experimental: Supervised strength training (group 2)
In-person, supervised muscle strengthening exercises twice weekly at a specific intensity.
Participants in this arm will complete twice weekly resistance training. They will focus on form initially, and then be progressed to 3 sets of ~4-6 repetitions at an intensity of 85% of estimated one repetition maximum, with a warm-up set of 8 repetitions at their estimated 70% estimated one repetition maximum to attempt to match the volume performed in the other resistance training group.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Lumbar Spine BMD
Time Frame: Baseline and 12 months
Lumbar spine (L1-L4) bone mineral density measured via DXA scan.
Baseline and 12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Fractures
Time Frame: Over 12 months
Composite outcome of new non-vertebral and vertebral fractures, and progression of existing vertebral fractures. We will report the number in each category separately. We will use a fracture questionnaire for non-vertebral fractures, and vertebral fractures that come to clinical attention. Participants will undergo a DXA scan for Vertebral Fracture Assessment (VFA) at baseline and the 12-months. A vertebral fracture will be defined as having a radiographic presence of ≥25% reduction in anterior, middle, or posterior vertebral height, verified by an experienced radiologist at University Health Network via the Genant visual semi-quantitative method. Baseline VFA will be assessed for vertebral fractures and compared to VFA at 12 months to ascertain if there has been progression of new fractures; progression will be defined as progression to a new Genant level or a change in height of at least 10%.
Over 12 months
Rate of falls per person per year
Time Frame: Over 12 months
Participants will be emailed a falls calendar via a REDCap survey at the end of each month. Participants will be asked to immediately report any falls to research assistant and to exercise physiologist. Exercise physiologists will report any noted falls to their study coordinator immediately and additional follow-up documentation will be required. Rate of falls and number of people who experience one or more falls will be compared between groups.
Over 12 months
Number of people who experience one or more falls
Time Frame: Over 12 months
Participants will be emailed a falls calendar via a REDCap survey at the end of each month. Participants will be asked to immediately report any falls to research assistant and to exercise physiologist. Exercise physiologists will report any noted falls to their study coordinator immediately and additional follow-up documentation will be required. Rate of falls and number of people who experience one or more falls will be compared between groups.
Over 12 months
Bone-free lean mass
Time Frame: Baseline and 12 months
Whole body fat- and bone-free lean mass (FBFM, kg) will be derived from DXA scans.
Baseline and 12 months
Appendicular lean mass
Time Frame: Baseline and 12 months
We will calculate appendicular lean mass (kg) and its index (kg/m^2) from appendicular bone-free lean mass and height (cm).
Baseline and 12 months
Height
Time Frame: Baseline and 12 months
Height will be a proxy measure of posture.
Baseline and 12 months
Occiput-to-wall distance
Time Frame: Baseline and 12 months
Occiput-to-wall distance will be a proxy measure of posture.
Baseline and 12 months
Knee extension peak torque
Time Frame: Baseline, 6 months, and 12 months
We will assess isometric knee extension peak torque using a knee extension test with a dynamometer.
Baseline, 6 months, and 12 months
30 Second Chair Stand Test.
Time Frame: Baseline, 6 months, and 12 months
We will use the 30 Second Chair Stand Test.
Baseline, 6 months, and 12 months
Four Square Step Test
Time Frame: Baseline, 6 months, and 12 months
We will use the Four Square Step Test to assess lower extremity muscle power and dynamic balance during functional tasks.
Baseline, 6 months, and 12 months
Grip Strength
Time Frame: Baseline, 6 months, and 12 months
We will assess grip strength of the non-dominant arm using a hand dynamometer.
Baseline, 6 months, and 12 months
10 Metre Walk Test.
Time Frame: Baseline, 6 months, and 12 months
We will assess gait speed using the 10 Metre Walk Test.
Baseline, 6 months, and 12 months
6 Minute Walk Test.
Time Frame: Baseline, 6 months, and 12 months
We will assess endurance using the 6 Minute Walk Test.
Baseline, 6 months, and 12 months
QUALEFFO-41
Time Frame: Baseline, 6 months, and 12 months
We will use the QUALEFFO-41 as an osteoporosis specific measure of health-related quality of life.
Baseline, 6 months, and 12 months
EQ5D5L
Time Frame: Baseline, 6 months, and 12 months
We will use the EQ5D5L measure as a generic health-related quality of life measure.
Baseline, 6 months, and 12 months
Serious adverse events
Time Frame: Over 12 months
We will ask participants to report adverse events, using Health Canada definitions. We will report all serious and non-serious adverse events and identify those attributable to intervention. Safety outcomes will include all falls, fractures, and serious and non-serious adverse events. Any fractures or falls that are attributable to intervention will be considered under both fall or fracture outcomes, and harms.
Over 12 months
Non-serious adverse events
Time Frame: Over 12 months
We will ask participants to report adverse events, using Health Canada definitions. We will report all serious and non-serious adverse events and identify those attributable to intervention. Safety outcomes will include all falls, fractures, and serious and non-serious adverse events. Any fractures or falls that are attributable to intervention will be considered under both fall or fracture outcomes, and harms.
Over 12 months
Glucose concentration
Time Frame: Baseline and 6 months
We will be taking a fasted blood sample from participants to measure plasma glucose concentrations using biochemical assay. Blood samples will only be collected from participants at the University of Waterloo site.
Baseline and 6 months
Insulin concentration
Time Frame: Baseline and 6 months
We will be taking a fasted blood sample from participants to measure serum insulin concentrations using radioimmunoassay. Blood samples will only be collected from participants at the University of Waterloo site.
Baseline and 6 months
Pro/anti-inflammatory markers (including TNFalpha, IL-6, IL-10, IL-15)
Time Frame: Baseline and 6 months
We will be taking a fasted blood sample from participants to measure plasma pro- and anti-inflammatory markers using a multiplex kit. Blood samples will only be collected from participants at the University of Waterloo site.
Baseline and 6 months
Oxidative stress markers/antioxidant status (including oxygen radical absorbance capacity (ORAC) assay, protein carbonyls, glutathione peroxidase activity, thyroredoxin, malondialdehyde)
Time Frame: Baseline and 6 months
We will be taking a fasted blood sample from participants to measure antioxidant status and markers of oxidative stress using commercially available assays. Blood samples will only be collected from participants at the University of Waterloo site.
Baseline and 6 months
Myokines
Time Frame: Baseline and 6 months
We will be taking fasting blood samples from participants to measure myokines via the Luminex Performance Assay. Blood samples will only be collected from participants at the University of Waterloo site.
Baseline and 6 months
Total Hip BMD
Time Frame: Baseline and 12 months
Bone mineral density of the hip measured via DXA scans
Baseline and 12 months
Femoral Neck BMD
Time Frame: Baseline and 12 months
Bone mineral density of the femoral neck measured via DXA scans
Baseline and 12 months
Trabecular Bone Score
Time Frame: Baseline and 12 months
Trabecular bone score (TBS) will be calculated using TBS iNsight software. A high TBS value indicates high quality boner structure, whereas a low TBS value demonstrates a lower quality structure. The TBS index ranges from 0.9 - 1.6.
Baseline and 12 months
Hip Geometry
Time Frame: Baseline and 12 months
We will use the DXA scanner's hip structural analysis feature to calculate estimates of hip geometry from proximal femur scans.
Baseline and 12 months
Health Service Use
Time Frame: Baseline, 6 months, and 12 months
We will assess direct medical resources (e.g., tests, medications, hospitalization, rehabilitation), direct non-medical resources (e.g., out of pocket expenses, transportation), indirect resources (e.g., iMTA Productivity Cost Questionnaire) and clinical events and management. We will assess resource use for incident falls, fractures or adverse events. Multiplying resources collected by jurisdictional unit costs in Canadian dollars will determine the total cost per exercise program.
Baseline, 6 months, and 12 months
Ratio of costs to QALY
Time Frame: Baseline, 6 months, and 12 months
We will calculate the ratio of incremental costs between the interventions, determined by trial resources, and clinical outcome (QALY) to achieve an incremental cost per life year gained outcome.
Baseline, 6 months, and 12 months
Willingness to pay
Time Frame: Baseline, 6 months, and 12 months
We will assess willingness to pay for various exercise models using a contingent valuation survey.
Baseline, 6 months, and 12 months
Body weight
Time Frame: Baseline, 6 months and 12 months
Body weight in kg measured using scale
Baseline, 6 months and 12 months

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Dietary Intake
Time Frame: Baseline, 6 months, and 12 months
We will use ASA24 to collect information on the participant's dietary intake through the self-administered 24-hour dietary record. Participants will report all food and beverage items and quantities on 3 days (2 weekday, 1 weekend day) at baseline, 6 months, and 12 months. We will also use the SCREEN2 tool at baseline only. We will report descriptive data on energy, protein, calcium, and vitamin D intake, and perform exploratory analyses of changes in these outcomes over time. We will perform subgroup analyses: 1) Baseline daily calcium (<1000 vs. >1000 mg per day); and 2) Baseline protein intake (<1.2g/kg body weight per day). We will explore changes in participants who are referred to a dietitian for counselling because of low intakes of protein, calcium, or vitamin D.
Baseline, 6 months, and 12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 13, 2022

Primary Completion (Anticipated)

September 1, 2026

Study Completion (Anticipated)

September 1, 2026

Study Registration Dates

First Submitted

July 6, 2022

First Submitted That Met QC Criteria

September 12, 2022

First Posted (Actual)

September 15, 2022

Study Record Updates

Last Update Posted (Actual)

November 4, 2022

Last Update Submitted That Met QC Criteria

November 1, 2022

Last Verified

November 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Osteoporosis

Clinical Trials on Home exercise

3
Subscribe